{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    7,
    8,
    9,
    10,
    11,
    19,
    20,
    21,
    23,
    24,
    25,
    26,
    27
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "ALXN1840 Treatment",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Single-arm treatment where participants receive ALXN1840 15 mg/day for 28 days followed by titration to 30 mg/day.",
        "extensionAttributes": [
          {
            "url": "x-titration",
            "valueString": "true"
          },
          {
            "url": "x-doseEpochs",
            "valueString": "[{'dose': '15 mg/day', 'startDay': 1, 'endDay': 28, 'description': 'Initial treatment period including accumulation and steady-state assessment.'}, {'dose': '30 mg/day', 'startDay': 29, 'endDay': 40, 'description': 'Titrated dose period following SRC safety review.'}]"
          }
        ]
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_1",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_1",
        "epochId": "epoch_6",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Cohort 1 (Treatment experienced)",
        "instanceType": "StudyCohort",
        "characteristic": "Patients who have received WD therapy for > 28 days"
      },
      {
        "id": "cohort_2",
        "name": "Cohort 2 (Treatment naïve)",
        "instanceType": "StudyCohort",
        "characteristic": "Patients who have received WD therapy for ≤ 28 days"
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "ALXN1840 Treatment - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for ALXN1840 Treatment during Screening"
      },
      {
        "id": "elem_2",
        "name": "ALXN1840 Treatment - Run-in Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for ALXN1840 Treatment during Run-in Period"
      },
      {
        "id": "elem_3",
        "name": "ALXN1840 Treatment - Inpatient Period 1",
        "instanceType": "StudyElement",
        "description": "Treatment period for ALXN1840 Treatment during Inpatient Period 1"
      },
      {
        "id": "elem_4",
        "name": "ALXN1840 Treatment - Outpatient Period",
        "instanceType": "StudyElement",
        "description": "Treatment period for ALXN1840 Treatment during Outpatient Period"
      },
      {
        "id": "elem_5",
        "name": "ALXN1840 Treatment - Inpatient Period 2",
        "instanceType": "StudyElement",
        "description": "Treatment period for ALXN1840 Treatment during Inpatient Period 2"
      },
      {
        "id": "elem_6",
        "name": "ALXN1840 Treatment - Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for ALXN1840 Treatment during Follow-up"
      }
    ],
    "summary": {
      "armCount": 1,
      "cellCount": 6,
      "cohortCount": 2,
      "elementCount": 6
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Non-Randomized",
        "codeSystem": "USDM",
        "decode": "Non-Randomized"
      },
      "controlType": {
        "code": "Historical Control",
        "codeSystem": "USDM",
        "decode": "Historical Control"
      },
      "armIds": [
        "arm_1"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Hepatology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Non-Randomized",
        "allocationRatio": null,
        "stratificationFactors": []
      },
      "controlType": "Historical Control",
      "therapeuticAreas": [
        "Hepatology"
      ]
    },
    "arms": [
      {
        "name": "ALXN1840 Treatment",
        "type": "Experimental Arm",
        "description": "Single-arm treatment where participants receive ALXN1840 15 mg/day for 28 days followed by titration to 30 mg/day.",
        "isTitration": true,
        "doseEpochs": [
          {
            "dose": "15 mg/day",
            "startDay": 1,
            "endDay": 28,
            "description": "Initial treatment period including accumulation and steady-state assessment."
          },
          {
            "dose": "30 mg/day",
            "startDay": 29,
            "endDay": 40,
            "description": "Titrated dose period following SRC safety review."
          }
        ]
      }
    ],
    "cohorts": [
      {
        "name": "Cohort 1 (Treatment experienced)",
        "characteristic": "Patients who have received WD therapy for > 28 days"
      },
      {
        "name": "Cohort 2 (Treatment naïve)",
        "characteristic": "Patients who have received WD therapy for ≤ 28 days"
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Up to 21 days prior to enrollment"
      },
      {
        "name": "Run-in Period",
        "description": "Day -7 to Day -1; includes diet equilibration and baseline copper/molybdenum balance measurement."
      },
      {
        "name": "Inpatient Period 1",
        "description": "Day -8 to Day 9; includes baseline and initial 15 mg/day accumulation phase."
      },
      {
        "name": "Outpatient Period",
        "description": "Day 9 to Day 23; maintenance of 15 mg/day dosing."
      },
      {
        "name": "Inpatient Period 2",
        "description": "Day 23 to Day 40; includes 15 mg steady state and 30 mg titration/steady state assessment."
      },
      {
        "name": "Follow-up",
        "description": "Post-treatment safety monitoring."
      }
    ]
  }
}